207 results on '"Miller, Timothy M."'
Search Results
2. Bringing platform trials closer to reality by enabling with digital research environment (DRE) connectivity
3. Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases
4. DNAJB6 isoform specific knockdown: Therapeutic potential for limb girdle muscular dystrophy D1
5. Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice
6. Disentangling glial diversity in peripheral nerves at single-nuclei resolution
7. Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD
8. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients
9. A viral toolkit for recording transcription factor–DNA interactions in live mouse tissues
10. Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negatives.
11. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
12. Tau Kinetics in Neurons and the Human Central Nervous System
13. A Path to High-Efficiency Optical Coupling for HIRMES
14. CNS microRNA profiles: a database for cell type enriched microRNA expression across the mouse central nervous system
15. Evaluating the efficacy of purchased antisense oligonucleotides to reduce mouse and human tau in vivo.
16. Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice.
17. Lumbar punctures are safe in patients with ALS and have a risk profile similar to that in the non‐ALS population.
18. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
19. Bax Deletion Further Orders the Cell Death Pathway in Cerebellar Granule Cells and Suggests a Caspase-Independent Pathway to Cell Death
20. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
21. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis
22. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
23. Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease
24. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia
25. Protein kinetics of superoxide dismutase‐1 in familial and sporadic amyotrophic lateral sclerosis.
26. Protective Effects of Lovastatin in a Population‐Based ALS Study and Mouse Model.
27. MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
28. Canine degenerative myelopathy: Biochemical characterization of superoxide dismutase 1 in the first naturally occurring non-human amyotrophic lateral sclerosis model
29. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
30. Is presymptomatic ALS perivascular?
31. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
32. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import
33. TDP-43 Mutant Transgenic Mice Develop Features of ALS and Frontotemporal Lobar Degeneration
34. Selective Association of Misfolded ALS-Linked Mutant SOD1 with the Cytoplasmic Face of Mitochondria
35. Gene Transfer Demonstrates That Muscle Is Not a Primary Target for Non-Cell-Autonomous Toxicity in Familial Amyotrophic Lateral Sclerosis
36. Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
37. Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review.
38. PRE-MORBID TYPE 2 DIABETES MELLITUS IS NOT A PROGNOSTIC FACTOR IN AMYOTROPHIC LATERAL SCLEROSIS
39. In vivo kinetic approach reveals slow SOD1 turnover in the CNS
40. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes
41. Design and Application of Electron-Transporting Organic Materials
42. Identification and Characterization of an Actin-Binding Site of CapZ
43. Incidence of amyotrophic lateral sclerosis in older adults.
44. TREM2 Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis
45. Indium Hybridization of Large Format TES Bolometer Arrays to Readout Multiplexers for Far-Infrared Astronomy
46. Antisense Oligonucleotides for the Study and Treatment of ALS.
47. Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial.
48. RCADiA: simple automation platform for comparative multidimensional protein identification technology
49. Antisense oligonucleotide therapy for neurodegenerative disease
50. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.